Pardes Biosciences Inc (PRDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 247,919 | 268,678 | 48 | 353 | 958 |
| TOTAL | $255,144 | $275,259 | $571 | $990 | $1,709 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 0 | 0 | 201,262 | 201,257 | 201,250 |
| TOTAL | $N/A | $N/A | $201,262 | $201,257 | $201,250 |
| Total Assets | $255,144 | $275,259 | $201,833 | $202,247 | $202,959 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,366 | 2,385 | 184 | 142 | 140 |
| Accrued Expenses | 6,397 | 6,580 | 2,165 | 1,453 | 51 |
| TOTAL | $8,763 | $8,965 | $2,498 | $1,694 | $240 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 208,294 | 195,553 | 197,719 |
| TOTAL | $N/A | $N/A | $208,294 | $195,553 | $197,719 |
| Total Liabilities | $8,763 | $8,965 | $210,791 | $197,247 | $197,959 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 62,321 | 62,379 | 25,759 | 25,759 | 25,759 |
| Common Shares | 6 | 6 | 1 | 1 | 1 |
| Retained earnings | -72,964 | -51,524 | -8,959 | -2,335 | -169 |
| TOTAL | $246,381 | $266,294 | $-8,959 | $5,000 | $5,000 |
| Total Liabilities And Equity | $255,144 | $275,259 | $201,833 | $202,247 | $202,959 |